Key facts
- It has raised $700K; the latest was Early Stage VC ($700K) in Sep 2025.
- Notable investors include AllerFund Ventures, The Consortium for Technology & Innovation in Pediatrics.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Anjo.ai
- ·The full record, as it builds
Funding rounds
No funding rounds for Anjo.ai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anjo.ai
Developer of a health disease detection technology intended to improve the quality of life and reduce medical costs for individuals who are at risk or diagnosed with severe allergic diseases. The company's technology utilizes artificial intelligence and patent-pending technology to predict and detect early signs of severe allergic reactions and offers personalized insights, continuous remote monitoring, and automatic monitoring to eliminate the need for subjective assessments and constant worry, enabling parents to take action and potentially save their child's life and physicians to make improved care decisions.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2022
- Employees
- 4
- Website
- anjo.ai/
- Ownership
- Privately Held (backing)
Anjo.ai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anjo.ai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anjo.ai in its N-PORT filings yet. We sweep new filings monthly.